Cargando…

Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma

In 40 patients with TNM stage T1 ovarian clear cell adenocarcinoma, we used nuclear morphometry to study the relations among morphometric variables, clinical prognostic factors and outcome. The presence of one or more giant nuclear cells was positively associated with death (OR = 10.6, P = 0.02) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, C Q, Sasaki, H, Fahey, M T, Sakamoto, A, Sato, S, Tanaka, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362809/
https://www.ncbi.nlm.nih.gov/pubmed/10206285
http://dx.doi.org/10.1038/sj.bjc.6690276
_version_ 1782153546380083200
author Liu, C Q
Sasaki, H
Fahey, M T
Sakamoto, A
Sato, S
Tanaka, T
author_facet Liu, C Q
Sasaki, H
Fahey, M T
Sakamoto, A
Sato, S
Tanaka, T
author_sort Liu, C Q
collection PubMed
description In 40 patients with TNM stage T1 ovarian clear cell adenocarcinoma, we used nuclear morphometry to study the relations among morphometric variables, clinical prognostic factors and outcome. The presence of one or more giant nuclear cells was positively associated with death (OR = 10.6, P = 0.02) and tended to be associated with disease recurrence (OR = 5.1, P = 0.07). Nuclear irregularity (expressed in terms of the nuclear roundness factor) was positively associated with both death (OR = 8.6, P = 0.02) and disease recurrence (OR = 8.2, P = 0.02). A combination of giant nuclear cell presence or nuclear irregularity proved to be a useful prognostic indicator, with a sensitivity and specificity of 83% and 71% in the prediction of death, and 75% and 71% in the prediction of disease recurrence. Patients' age and substage were of no prognostic value. We conclude that the nuclear morphometric characteristics, especially the presence of giant nuclear cells and nuclear irregularity, may be useful in predicting outcome in patients with early stage ovarian clear cell adenocarcinoma. © 1999 Cancer Research Campaign
format Text
id pubmed-2362809
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23628092009-09-10 Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma Liu, C Q Sasaki, H Fahey, M T Sakamoto, A Sato, S Tanaka, T Br J Cancer Regular Article In 40 patients with TNM stage T1 ovarian clear cell adenocarcinoma, we used nuclear morphometry to study the relations among morphometric variables, clinical prognostic factors and outcome. The presence of one or more giant nuclear cells was positively associated with death (OR = 10.6, P = 0.02) and tended to be associated with disease recurrence (OR = 5.1, P = 0.07). Nuclear irregularity (expressed in terms of the nuclear roundness factor) was positively associated with both death (OR = 8.6, P = 0.02) and disease recurrence (OR = 8.2, P = 0.02). A combination of giant nuclear cell presence or nuclear irregularity proved to be a useful prognostic indicator, with a sensitivity and specificity of 83% and 71% in the prediction of death, and 75% and 71% in the prediction of disease recurrence. Patients' age and substage were of no prognostic value. We conclude that the nuclear morphometric characteristics, especially the presence of giant nuclear cells and nuclear irregularity, may be useful in predicting outcome in patients with early stage ovarian clear cell adenocarcinoma. © 1999 Cancer Research Campaign Nature Publishing Group 1999-04 /pmc/articles/PMC2362809/ /pubmed/10206285 http://dx.doi.org/10.1038/sj.bjc.6690276 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Liu, C Q
Sasaki, H
Fahey, M T
Sakamoto, A
Sato, S
Tanaka, T
Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma
title Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma
title_full Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma
title_fullStr Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma
title_full_unstemmed Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma
title_short Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma
title_sort prognostic value of nuclear morphometry in patients with tnm stage t1 ovarian clear cell adenocarcinoma
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362809/
https://www.ncbi.nlm.nih.gov/pubmed/10206285
http://dx.doi.org/10.1038/sj.bjc.6690276
work_keys_str_mv AT liucq prognosticvalueofnuclearmorphometryinpatientswithtnmstaget1ovarianclearcelladenocarcinoma
AT sasakih prognosticvalueofnuclearmorphometryinpatientswithtnmstaget1ovarianclearcelladenocarcinoma
AT faheymt prognosticvalueofnuclearmorphometryinpatientswithtnmstaget1ovarianclearcelladenocarcinoma
AT sakamotoa prognosticvalueofnuclearmorphometryinpatientswithtnmstaget1ovarianclearcelladenocarcinoma
AT satos prognosticvalueofnuclearmorphometryinpatientswithtnmstaget1ovarianclearcelladenocarcinoma
AT tanakat prognosticvalueofnuclearmorphometryinpatientswithtnmstaget1ovarianclearcelladenocarcinoma